Relation between HER-2 gene expression and prognostic prostate cancer parameters in trus guided biopsies

Document Type : Original Article


1 Department of Pathology,Faculty of Medicine,Mashhad University of Medical Sciences,Mashhad,Iran.

2 Kidney Transplantation and Complications Research Center,Mashhad University of Medical Sciences,Mashhad,Iran.

3 Students Research Committee,Mashhad University of Medical Sciences, Mashhad, Iran.

4 Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.


Introduction: Prostate carcinoma is the most common type of cancer and the second lethal cancer in men. Overexpression of Her2-neu gene affects the growth and prognosis of some tumors. HER2 gene amplification is seen in about one-third of prostatic adenocarcinoma also seems to correlate with androgen independence of the prostate tumors. We evaluated the HER2-neu expression in prostate cancer and its relation with known prognostic factors, in this study.
Material and Methods: Immunohistochemical staining was used to evaluate the expression of Her2-neu in 60 cases of prostate carcinoma. The relation between HER2-neu expression and prognostic factors of prostatic carcinoma was evaluated,which included serum PSA values , number of core involvement, high percentage of core involvement,Gleason score,Gleason grade,extra prostatic extension of the tumoral cells and tumor volume.
Results: Among 60 patients included in our study ,Her2-neu was negative in 49 (81.7%) cases (zero score in 35 cases and score 1+ in 14 cases) , and a weakly positive expression (score 2+) was seen in 11 (%18/3) cases.Among evaluated factors, tumor volume was the only factor which significantly correlated with Her2-neu expression.
Conclusion:The rate of Her2-neu expression was not high in our patients. Among various variables evaluated in our study,only tumor volume had significant statistical correlation with the expression of Her2-neu. According to low expression of Her2-neu in evaluated specimens in this study, it is necessary to conduct more studies to confirm the relationship of her2-neu and the known prognostic factors of prostate carcinoma.


1. Kolahdoozan S, Sadjadi A, Radmard AR, Khademi H.Five common cancers in Iran. Arch Iran Med. 2010;13(2):143-6. 
2. Tao Z, Shi A, Wang K, Zhang W. Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci. 2015; 19(5):805-12. 
3. Bashir MN. Epidemiology of prostate cancer. Asian Pac J Cancer Prev. 2015; 16(13):5137-41. 
4. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018; 8(12):a030361. 
5. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19(13):3159-67. 
6. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C.From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci.1999; 96(10):5458-63. 
7. Edwards J, Mukherjee R, Munro AF, Wells AC, Almushatat A, Bartlett JM. HER2 and COX2 expression in human prostate cancer. Eur J Cancer.2004; 40(1):50-5. 
8. Fonseca GN, Srougi M, Leite KR, Nesrallah LJ, Ortiz V. The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma. Sao Paulo Med J. 2004; 122(3):124-7. 
9. Lara PN, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Kauderer C, et al. HER‐2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer. 2002; 94(10): 2584-9. 
10. Carles J, Lloreta J, Salido M, Font A, Suarez M, Baena V, et al. Her-2/neu expression in prostate cancer: a dynamic process? Clin Cancer Res. 2004;10(14):4742-5. 
11. Nishio Y, Yamada Y, Kokubo H, Nakamura K, Aoki S, Taki T, et al. Prognostic significance of immunohistochemical expression of the HER2/neu oncoprotein in bone metastatic prostate cancer. Urology. 2006; 68(1):110-5. 
12. Rubin MA, Girelli G, Demichelis F. Genomic correlates to the newly proposed grading prognostic groups for prostate cancer. Eur Urol. 2016; 69(4):557-60.
13. Sauter G, Steurer S, Clauditz TS, Krech T, Wittmer C, Lutz F, et al. Clinical utility of quantitative Gleason grading in prostate biopsies and prostatectomy specimens. Eur Urol. 2016; 69(4):592-8. 
14. Sadjadi A, Nooraie M, Ghorbani A, Alimohammadian M, Zahedi MJ, Darvish-Moghadam S, et al. The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iran Med.2007; 10(4):481-5. 
15. Mofid B, Jalali Nodushan M, Rakhsha A, Zeinali L, Mirzaei H. Relation between HER-2 gene expression and Gleason score in patients with prostate cancer. Urol J. 2009; 4(2):101-4. 
16. Siampanopoulou M, Galaktidou G, Dimasis N,Gotzamani-Psarrakou A. Profiling serum HER2/NEU in prostate  cancer. Hippokratia. 2013;17(2):108-12. 
17. Baltaci S. Her-2/neu oncogene expression in prostate carcinoma: evaluation of gene amplification by FISH method. Turkish J Pathol.2008; 24(2):76-83. 
18. Fantinato AP, Tobias-Machado M, Fonseca F, Pinto JL, Wroclawski ML, Wroclawski E, et al. HER2/neu expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients. Tumori. 2007; 93(5):467-72. 
19. Zhang YF, Guan YB, Yang B, Wu HY, Dai YT, Zhang SJ, et al. Prognostic value of Her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer. Chin Med J. 2011; 124(24):4345-9. 
20. Shuch B, Mikhail M, Satagopan J, Lee P, Yee H, Chang C, et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol. 2004; 22(23):4725-9. 
21. Mofid B, Nadoushan MJ, Rakhsha A, Mirzaei H, Zeinali L. Epidermal growth factor receptor gene in prostate cancer after radical prostatectomy. Iran J Cancer Prev. 2010; 3(4):174-7.